Your browser doesn't support javascript.
loading
Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension.
Le Ribeuz, Hélène; To, Lucie; Ghigna, Maria-Rosa; Martin, Clémence; Nagaraj, Chandran; Dreano, Elise; Rucker-Martin, Catherine; Girerd, Barbara; Bouligand, Jérôme; Pechoux, Christine; Lambert, Mélanie; Boet, Angèle; Issard, Justin; Mercier, Olaf; Hoetzenecker, Konrad; Manoury, Boris; Becq, Frédéric; Burgel, Pierre-Régis; Cottart, Charles-Henry; Olschewski, Andrea; Sermet-Gaudelus, Isabelle; Perros, Frédéric; Humbert, Marc; Montani, David; Antigny, Fabrice.
Afiliación
  • Le Ribeuz H; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.
  • To L; INSERM UMR_S 999 "Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
  • Ghigna MR; Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
  • Martin C; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.
  • Nagaraj C; INSERM UMR_S 999 "Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
  • Dreano E; Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
  • Rucker-Martin C; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.
  • Girerd B; INSERM UMR_S 999 "Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
  • Bouligand J; Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
  • Pechoux C; Hôpitaux de Paris (AP-HP), Dept of Respiratory Medicine, Centre de Référence Maladie Rare Mucoviscidose, ERN-Lung, Cochin Hospital, Paris, France.
  • Lambert M; Inserm U1016, Institut Cochin, Université de Paris, Paris, France.
  • Boet A; Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.
  • Issard J; Inserm U1151 - CNRS UMR 8253 - Institut Necker Enfants Malades, Centre Maladie Rare Mucoviscidose, ERN Lung, Université de Paris, Paris, France.
  • Mercier O; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.
  • Hoetzenecker K; INSERM UMR_S 999 "Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
  • Manoury B; Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
  • Becq F; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.
  • Burgel PR; INSERM UMR_S 999 "Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
  • Cottart CH; Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
  • Olschewski A; Laboratoire de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
  • Sermet-Gaudelus I; INSERM UMR-1185, Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.
  • Perros F; GABI, INRA, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France.
  • Humbert M; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.
  • Montani D; INSERM UMR_S 999 "Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
  • Antigny F; Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
Eur Respir J ; 58(5)2021 11.
Article en En | MEDLINE | ID: mdl-33926975
ABSTRACT

INTRODUCTION:

A reduction in pulmonary artery relaxation is a key event in the pathogenesis of pulmonary arterial hypertension (PAH). Cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction in airway epithelial cells plays a central role in cystic fibrosis; CFTR is also expressed in pulmonary arteries and has been shown to control endothelium-independent relaxation. AIM AND

OBJECTIVES:

We aimed to delineate the role of CFTR in PAH pathogenesis through observational and interventional experiments in human tissues and animal models. METHODS AND

RESULTS:

Reverse-transcriptase quantitative PCR, confocal imaging and electron microscopy showed that CFTR expression was reduced in pulmonary arteries from patients with idiopathic PAH (iPAH) and in rats with monocrotaline-induced pulmonary hypertension (PH). Moreover, using myography on human, pig and rat pulmonary arteries, we demonstrated that CFTR activation induces pulmonary artery relaxation. CFTR-mediated pulmonary artery relaxation was reduced in pulmonary arteries from iPAH patients and rats with monocrotaline- or chronic hypoxia-induced PH. Long-term in vivo CFTR inhibition in rats significantly increased right ventricular systolic pressure, which was related to exaggerated pulmonary vascular cell proliferation in situ and vessel neomuscularisation. Pathologic assessment of lungs from patients with severe cystic fibrosis (F508del-CFTR) revealed severe pulmonary artery remodelling with intimal fibrosis and medial hypertrophy. Lungs from homozygous F508delCftr rats exhibited pulmonary vessel neomuscularisation. The elevations in right ventricular systolic pressure and end diastolic pressure in monocrotaline-exposed rats with chronic CFTR inhibition were more prominent than those in vehicle-exposed rats.

CONCLUSIONS:

CFTR expression is strongly decreased in pulmonary artery smooth muscle and endothelial cells in human and animal models of PH. CFTR inhibition increases vascular cell proliferation and strongly reduces pulmonary artery relaxation.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Regulador de Conductancia de Transmembrana de Fibrosis Quística / Hipertensión Arterial Pulmonar Tipo de estudio: Etiology_studies Límite: Animals / Humans Idioma: En Revista: Eur Respir J Año: 2021 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Regulador de Conductancia de Transmembrana de Fibrosis Quística / Hipertensión Arterial Pulmonar Tipo de estudio: Etiology_studies Límite: Animals / Humans Idioma: En Revista: Eur Respir J Año: 2021 Tipo del documento: Article País de afiliación: Francia